Abstract 5577: Short-Term Outcomes of STEMI and NSTEMI in Patients with Chronic Kidney Disease: A Report from the National Cardiovascular Data ACTION Registry

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Caroline S Fox ◽  
Paul Muntner ◽  
Anita Y Chen ◽  
Karen P Alexander ◽  
Matthew T Roe ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Beta Blockers ◽  
The United States ◽  
Relative Increase ◽  
High Risk Population ◽  
Major Bleed ◽  
Mdrd Equation ◽  
Ckd Stage ◽  
Study Population

Chronic kidney disease (CKD) is a risk factor for myocardial infarction (MI) and death. However, the relationship between severity of CKD and contemporary hospital-based management and outcomes across the spectrum of MI (STEMI and NSTEMI) has not been well-documented. The study population was drawn from the ACTION Registry, a nation-wide sample of STEMI (n=19,481) and NSTEMI (n=30,462) patients admitted to 274 hospitals in the United States between January 1 and December 31, 2007. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) equation and categorized as ≥60, 30 to <60, 15 to <30 and eGFR<15 mL/min/1.73m 2 or dialysis. Use of acute (first 24 hours) therapies and early (first 48 hours) cardiac catheterization as well as in-hospital major bleeds, and death were compared across CKD stages in models adjusted for demographics, CVD history and prior procedures, and risk factors. Overall, 30.5% and 42.9% of patients with STEMI and NSTEMI, respectively, had CKD Stage III or greater (eGFR<60 ml/min/1.73m 2 or dialysis). Regardless of MI type, patients with CKD were less likely to receive acute evidence-based therapies including aspirin, beta-blockers or clopidogrel or to undergo early invasive care and were more likely to experience a major bleed or death (Table ). There were 1030 deaths among those presenting with STEMI, and 1223 among those with NSTEMI. There was a greater relative increase in death for patients with STEMI with advancing CKD stage than was seen in NSTEMI (P interaction <0.0001 for each stage). A large proportion of patients presenting with STEMI or NSTEMI have CKD. Further efforts to address treatment gaps in the management of MI in the presence of CKD are needed to improve outcomes in this high-risk population. Table- Multivariable adjusted odds ratios and 95% confidence intervals of outcomes based on CKD stage

Chronic kidney disease

2020 ◽  
pp. 4830-4860
Author(s):  
Alastair Hutchison
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Renal Disease ◽  
Replacement Therapy ◽  
The United States ◽  
Protein Excretion ◽  
Stage 4 ◽  
Ckd Stage ◽  
Stage 1

Chronic kidney disease (CKD) is defined as kidney damage lasting for more than 3 months characterized by structural or functional abnormalities of the kidney, with or without decreased glomerular filtration rate (GFR). CKD has been subdivided into six stages depending on the estimated GFR (eGFR) and degree of proteinuria: CKD stage 1 is eGFR greater than 90 ml/min (per 1.73 m2) with other evidence of renal disease; CKD stage 2 is eGFR 60 to 89 ml/min, with other evidence of renal disease; CKD stage 3a is eGFR 45 to 59 ml/min; CKD stage 3b is eGFR 30 to 44 ml/min; CKD stage 4 is eGFR 15 to 29 ml/min; and CKD stage 5 is eGFR less than 15 ml/min. At each stage the CKD is further categorized according to the degree of proteinuria based on the albumin:creatinine ratio (ACR), from A1 (no increase in protein excretion) to A3 (severe proteinuria). The eGFR is least accurate when the serum creatinine is within or near the normal range. Mild CKD is common, with about 10% of the population of the United States of America having CKD stage 1, 2, or 3 (combined), but advanced CKD is relatively rare (about 0.2% are receiving renal replacement therapy). Patients with CKD stage 1, 2, or 3 are at relatively low risk of progressing to require renal replacement therapy, but are at high risk of death from cardiovascular disease. This chapter discusses the definition, aetiology, and pathophysiology of CKD, followed by sections on the prevention of progression, medical management of the consequences of CKD (including diet, CKD mineral and bone disorders, advanced hyperparathyroidism, and anaemia), and preparation for renal replacement therapy or conservative management of uraemia.

Outcome of Febuxostat treatment in hyperuricemic pre-dialysis chronic kidney disease patients

2020 ◽  
Vol 7 (2) ◽  
pp. 45-52
Author(s):  
Dineshowri Shrestha ◽  
Anil Baral ◽  
Kashyap Dahal ◽  
Juju Raj Shrestha ◽  
Rajani Hada
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Kidney Disease ◽  
Adverse Effects ◽  
Serum Uric Acid ◽  
Kidney Injury ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Mdrd Equation ◽  
Ckd Stage

Introduction: Hyperuricemia is a cause and effect of chronic kidney disease (CKD), accelerates its progression and predisposes to acute kidney injury. Present study aimed to find out the outcome of Febuxostat treatment in hyperuricemic pre-dialysis CKD patients. Method: This was a cross sectional study conducted in Nephrology department, Bir hospital, Nepal, during from February 2019 to January 2020, among pre-dialysis CKD stage 3-5 non dialysis (ND) patients with serum uric acid (SUA) >7 mg/d L who were treated with Febuxostat 40 mg once a day and followed up at one, two and three months. The baseline SUA, creatinine, estimated glomerular filtration rate (eGFR) calculated by the modification of diet in renal disease (MDRD) equation compared with values at follow up and according to CKD stages. The adverse effects and liver enzymes were recorded. Result: There were total 50 patients, mean age 54.2±16.5 years, male 31 (62%).There were significant reductions of SUA from baseline of 8.9±1.4to 7.1±1.2 vs 5.9±0.9 vs 4.7±1.0) at one, two and three month respectively, p=0.000 and increment of eGFR (ml/min/1.73m2) from 29.6±15.0 to 31.6±16.0, 33.6±16.6, 34.1±17.1, p=0.000.And 41 (82%) patients achieved uric acid < 6 mg/dl at three month. Significant reduction of uric acid in all CKD stages and increment of eGFR in CKD stage 3 and 4 were observed. Adverse effects were epigastralgia in 5 (10%) and joint pain in 13 (26%). Conclusion: Febuxostat is an effective serum uric acid lowering drug in pre-dialysis chronic kidney disease patients with improvement of kidney function.

Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease

2018 ◽  
Vol 52 (11) ◽  
pp. 1078-1084 ◽  
Author(s):  
Joseph H. Schafer ◽  
Ashley L. Casey ◽  
Kristina A. Dupre ◽  
Britta A. Staubes
Keyword(s):  
Chronic Kidney Disease ◽  
Ischemic Stroke ◽  
Kidney Disease ◽  
Major Bleeding ◽  
Warfarin Therapy ◽  
Advanced Chronic Kidney Disease ◽  
Major Bleed ◽  
Time Period ◽  
Stage 4 ◽  
Ckd Stage

Background: Because of a lack of comparative data on anticoagulant use in the advanced chronic kidney disease (CKD) population, guidelines recommend warfarin for atrial fibrillation and venous thromboembolism (VTE) treatment in these patients. However, apixaban has specific dosing recommendations in CKD leading to use in clinical practice. Objective: To evaluate major bleeding, stroke, and thromboembolism rates in patients with CKD stage 4, stage 5, and dialysis on apixaban or warfarin therapy. Methods: This was a retrospective cohort study of patients with advanced CKD receiving apixaban or warfarin. The primary outcome was the occurrence of major bleeding at 3 months after enrollment. Secondary outcomes included occurrence of major bleeding, occurrence of ischemic stroke, and recurrence of VTE at 3 to 6 and 6 to 12 months. Results: A total of 604 patients were included in the analysis. The percentage of apixaban and warfarin patients with a major bleed at 0 to 3, 3 to 6, and 6 to 12 months were 8.3% versus 9.9% ( P=0.48), 1.4% versus 4% ( P=0.07), and 1.5% versus 8.4% ( P<0.001), respectively. There were no differences in rates of ischemic stroke or recurrent VTE at any time period. Conclusion and Relevance: Patients with advanced CKD taking apixaban had similar bleeding rates at 3 months compared with those taking warfarin. However, those who continued therapy had higher major bleeding rates with warfarin between 6 and 12 months. This study provides knowledge on the effects of a direct oral anticoagulant in a population that was excluded from all major trials.

scholarly journals Data Augmentation Based on Generative Adversarial Networks to Improve Stage Classification of Chronic Kidney Disease

2021 ◽  
Vol 12 (1) ◽  
pp. 352
Author(s):  
Yun-Te Liao ◽  
Chien-Hung Lee ◽  
Kuo-Su Chen ◽  
Chie-Pein Chen ◽  
Tun-Wen Pai
Keyword(s):  
Chronic Kidney Disease ◽  
Deep Learning ◽  
Kidney Disease ◽  
Classification System ◽  
Training Model ◽  
The United States ◽  
Generative Adversarial Networks ◽  
Generation Model ◽  
Ckd Stage ◽  
Gp Model

The prevalence of chronic kidney disease (CKD) is estimated to be 13.4% worldwide and 15% in the United States. CKD has been recognized as a leading public health problem worldwide. Unfortunately, as many as 90% of CKD patients do not know that they already have CKD. Ultrasonography is usually the first and the most commonly used imaging diagnostic tool for patients at risk of CKD. To provide a consistent assessment of the stage classifications of CKD, this study proposes an auxiliary diagnosis system based on deep learning approaches for renal ultrasound images. The system uses the ACWGAN-GP model and MobileNetV2 pre-training model. The images generated by the ACWGAN-GP generation model and the original images are simultaneously input into the pre-training model MobileNetV2 for training. This classification system achieved an accuracy of 81.9% in the four stages of CKD classification. If the prediction results allowed a higher stage tolerance, the accuracy could be improved by up to 90.1%. The proposed deep learning method solves the problem of imbalance and insufficient data samples during training processes for an automatic classification system and also improves the prediction accuracy of CKD stage diagnosis.

Ultrasound-guided peripheral intravenous access in chronic kidney disease patients

2021 ◽  
pp. 112972982110122
Author(s):  
Lauren Icken ◽  
Ellora V Sharma ◽  
Jon W Schrock ◽  
Anne P Lally ◽  
Samuel J Tate ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
The United States ◽  
Survey Study ◽  
Success Rates ◽  
Ultrasound Guided ◽  
Long Term Effect ◽  
Ckd Stage ◽  
Peripheral Intravenous Access ◽  
The Impact

Objective: Ultrasound-guided peripheral intravenous (USPIV) catheters are being placed in emergency department (ED) patients with increasing frequency. USPIV catheters have been shown to improve the success rates of cannulation. It is unknown what the long-term effect of USPIV placement will be on fistula creation in chronic kidney disease (CKD) patients considering these ultrasound-guided peripheral lines often target the same deeper vessels used for fistulas. This study aimed to survey whether emergency medicine programs place restrictions on USPIV placement in patients with CKD stages 3–5. Methods: This was a survey study encompassing all 110 emergency ultrasound fellowship directors in the United States at the time the survey was conducted. Data was collected on an anonymous and voluntary basis. The primary outcome was the number of programs with restrictions on USPIV placement in patients with CKD stage 3 or greater. Results: Of the 56 programs that responded, 21% reported having policies limiting which patients were appropriate for USPIV. Despite this, only one program reported placing restrictions on USPIV in CKD stage 3 or greater ( p < 0.0001). Conclusions: Emergency departments do not have or follow restrictions placed on USPIV placement in patients with CKD stage 3 or greater. The use of these veins in the ED may result in thrombosis as well as inflammation and permanent scarring which could negatively impact the ability to utilize those vessels for fistula creation. Future studies are needed to further characterize the impact of USPIV on fistula creation.

scholarly journals Risk of Atherosclerotic Cardiovascular Disease and Nonatherosclerotic Cardiovascular Disease Hospitalizations for Triglycerides Across Chronic Kidney Disease Stages Among 2.9 Million US Veterans

2021 ◽  
Author(s):  
Melissa Soohoo ◽  
Leila Hashemi ◽  
Jui‐Ting Hsiung ◽  
Hamid Moradi ◽  
Matthew J. Budoff ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
High Risk Population ◽  
Atherosclerotic Cardiovascular Disease ◽  
Time Varying ◽  
Cox Models ◽  
Ckd Stage ◽  
Relationship Of ◽  
The Impact

Background High triglycerides are associated with atherosclerotic cardiovascular disease (ASCVD) risks. Among patients with advanced chronic kidney disease (CKD), the association of elevated triglycerides with mortality is diminished and, thus, we investigated the relationship of triglycerides with ASCVD and non‐ASCVD hospitalizations across CKD stages. Methods and Results The cohort comprised 2 963 176 veterans who received care in 2004 to 2006 (baseline) and were followed up to 2014. Using Cox models, we evaluated baseline and time‐varying triglycerides with time to ASCVD or non‐ASCVD hospitalizations, stratified by baseline CKD stage, and adjusted for demographics and baseline or time‐updated clinical characteristics. The cohort mean±SD age was 63±14 years, with a baseline median (interquartile range) triglycerides level of 127 (87–189) mg/dL, and a quarter had prevalent CKD. There was a linear association between baseline triglycerides and ASCVD risk; however, the risk with high triglycerides ≥240 mg/dL attenuated with worsening CKD stages (reference: triglycerides 120 to <160 mg/dL). Baseline triglycerides were associated with a U‐shaped relationship for non‐ASCVD events in patients with CKD 3A to 3B. Patients with late‐stage CKD had lower to null relationships between baseline triglycerides and non‐ASCVD events. Time‐varying triglycerides associations with ASCVD were similar to baseline analyses. Yet, the time‐varying triglycerides relationship with non‐ASCVD events was inverse and linear, where elevated triglycerides were associated with lower risks. Conclusions Associations of higher triglycerides with ASCVD and non‐ASCVD events declined across advancing CKD stages, where a lower to null risk was observed in patients with advanced CKD. Studies are needed to examine the impact of advanced CKD on triglycerides metabolism and its association with outcomes in this high‐risk population.

scholarly journals Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification: a cohort study in primary care

2018 ◽  
Vol 68 (673) ◽  
pp. e524-e530 ◽  
Author(s):  
Jennifer A Hirst ◽  
Maria DLA Vazquez Montes ◽  
Clare J Taylor ◽  
José M Ordóñez-Mena ◽  
Emma Ogburn ◽  
...  
Keyword(s):  
Primary Care ◽  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Kidney Disease ◽  
Estimating Equation ◽  
Primary Care Population ◽  
Mdrd Equation ◽  
Ckd Stage ◽  
Diagnosis And Classification ◽  
The Impact

BackgroundChronic kidney disease (CKD) is diagnosed using the estimated glomerular filtration rate (eGFR) and the urinary albumin:creatinine ratio (ACR). The eGFR is calculated from serum creatinine levels using the Modification of Diet in Renal Disease (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.AimTo compare the performance of one versus two eGFR/ACR measurements, and the impact of equation choice, on CKD diagnosis and classification.Design and settingCohort study in primary care in the Thames Valley region of the UK.MethodData were from 485 participants aged >60 years in the Oxford Renal Cohort Study with at least two eGFR tests. The proportion of study participants diagnosed and classified into different CKD stages using one and two positive tests were compared. Prevalence of CKD diagnosis and classification by CKD stage were compared when eGFR was calculated using MDRD and CKD-EPI equations.ResultsParticipants included in the analysis had a mean age of 72.1 (±6.8) years and 57.0% were female. Use of a single screening test overestimated the proportion of people with CKD by around 25% no matter which equation was used, compared with the use of two tests. The mean eGFR was 1.4 ml/min/1.73 m2 (95% CI = 1.1 to 1.6) higher using the CKD-EPI equation compared with the MDRD equation. More patients were diagnosed with CKD when using the MDRD equation, compared with the CKD-EPI equation, once (64% versus 63%, respectively) and twice (39% versus 38%, respectively), and 16 individuals, all of who had CKD stages 2 or 3A with MDRD, were reclassified as having a normal urinary ACR when using the CKD-EPI equation.ConclusionCurrent guidance to use two eGFR measures to diagnose CKD remains appropriate in an older primary care population to avoid overdiagnosis. A change from MDRD to CKD-EPI equation could result in one in 12 patients with a CKD diagnosis with MDRD no longer having a diagnosis of CKD.

scholarly journals Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions

2016 ◽  
Vol 44 (2) ◽  
pp. 130-140 ◽  
Author(s):  
Michael V. Rocco ◽  
Arlene Chapman ◽  
Glenn M. Chertow ◽  
Debbie Cohen ◽  
Jing Chen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
Systolic Blood Pressure ◽  
Disease Classification ◽  
Intervention Trial ◽  
Mdrd Equation ◽  
Ckd Stage ◽  
Lower Egfr

Background: Interventional trials have used either the Modification of Diet in Renal Disease (MDRD) or chronic kidney disease (CKD)-Epidemiology Collaboration (CKD-EPI) equation for determination of estimated glomerular filtration rate (eGFR) to define whether participants have stages 3-5 CKD. The equation used to calculate eGFR may influence the number and characteristics of participants designated as having CKD. Methods: We examined the classification of CKD at baseline using both equations in the Systolic Blood Pressure Intervention Trial (SPRINT). eGFR was calculated at baseline using fasting serum creatinine values from a central laboratory. Results: Among 9,308 participants with baseline CKD classification using the 4-variable MDRD equation specified in the SPRINT protocol, 681 (7.3%) participants were reclassified to a less advanced CKD stage (higher eGFR) and 346 (3.7%) were reclassified to a more advanced CKD stage (lower eGFR) when the CKD-EPI equation was used to calculate eGFR. For eGFRs <90 ml/min/1.73 m2, participants <75 years were more likely to be reclassified to a less advanced CKD stage; this reclassification was more likely to occur in non-blacks rather than blacks. Participants aged ≥75 years were more likely to be reclassified to a more advanced than a less advanced CKD stage, regardless of baseline CKD stage. Reclassification of baseline CKD status (eGFR <60 ml/min/1.73 m2) occurred in 3% of participants. Conclusions: Use of the MDRD equation led to a higher percentage of participants being classified as having CKD stages 3-4. Younger and non-black participants were more likely to be reclassified as not having CKD using the CKD-EPI equation.

scholarly journals Cardiovascular Disease in Chronic Kidney Disease

Circulation ◽  
2021 ◽  
Vol 143 (11) ◽  
pp. 1157-1172
Author(s):  
Joachim Jankowski ◽  
Jürgen Floege ◽  
Danilo Fliser ◽  
Michael Böhm ◽  
Nikolaus Marx
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Accelerated Aging ◽  
High Risk Population ◽  
Atherosclerotic Lesions ◽  
Ckd Stage ◽  
Clinical Consequences ◽  
Artery Disease ◽  
End Stage

Patients with chronic kidney disease (CKD) exhibit an elevated cardiovascular risk manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. Although the incidence and prevalence of cardiovascular events is already significantly higher in patients with early CKD stages (CKD stages 1–3) compared with the general population, patients with advanced CKD stages (CKD stages 4–5) exhibit a markedly elevated risk. Cardiovascular rather than end-stage kidney disease (CKD stage 5) is the leading cause of death in this high-risk population. CKD causes a systemic, chronic proinflammatory state contributing to vascular and myocardial remodeling processes resulting in atherosclerotic lesions, vascular calcification, and vascular senescence as well as myocardial fibrosis and calcification of cardiac valves. In this respect, CKD mimics an accelerated aging of the cardiovascular system. This overview article summarizes the current understanding and clinical consequences of cardiovascular disease in CKD.

Sign in / Sign up

Export Citation Format

Share Document